Scientists have identified a molecule called SU212 that blocks the growth of triple-negative breast cancer (TNBC), an aggressive form of the disease.
SU212 is derived from aza-podophyllotoxin and inhibits ENO1, a glycolytic enzyme overexpressed in cancer cells. This inhibition reduces tumour cell activity and slows tumour growth in preclinical models.
The molecule also improved liver health and lowered blood sugar levels in diabetic mice.
Researchers say SU212 has a favorable safety profile with minimal toxicity, offering a new approach to treat TNBC while addressing metabolic disorders.